Literature DB >> 10330420

DeltaF508 CFTR protein expression in tissues from patients with cystic fibrosis.

N Kälin1, A Claass, M Sommer, E Puchelle, B Tümmler.   

Abstract

Heterologous expression of the cystic fibrosis transmembrane conductance regulator (CFTR) provided evidence that the major cystic fibrosis (CF) mutation DeltaF508 leads to defective protein folding in the endoplasmic reticulum, which prevents its processing and targeting to the cell surface. In this study, we investigated endogenous CFTR expression in skin biopsies and respiratory and intestinal tissue specimens from DeltaF508 homozygous and non-CF patients, using immunohistochemical and immunoblot analyses with a panel of CFTR antibodies. CFTR expression was detected at the luminal surface of reabsorptive sweat ducts and airway submucosal glands, at the apex of ciliated cells in pseudostratified respiratory epithelia and of isolated cells of the villi of duodenum and jejunum, and within intracellular compartments of intestinal goblet cells. In DeltaF508 homozygous patients, expression of the mutant protein proved to be tissue specific. Whereas DeltaF508 CFTR was undetectable in sweat glands, the expression in the respiratory and intestinal tracts could not be distinguished from the wild-type by signal intensity or localization. The tissue-specific variation of DeltaF508 CFTR expression from null to apparently normal amounts indicates that DeltaF508 CFTR maturation can be modulated and suggests that determinants other than CFTR mislocalization should play a role in DeltaF508 CF respiratory and intestinal disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10330420      PMCID: PMC408454          DOI: 10.1172/JCI5731

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  73 in total

1.  Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein.

Authors:  C R Brown; L Q Hong-Brown; J Biwersi; A S Verkman; W J Welch
Journal:  Cell Stress Chaperones       Date:  1996-06       Impact factor: 3.667

2.  Mice deficient in lysosomal acid phosphatase develop lysosomal storage in the kidney and central nervous system.

Authors:  P Saftig; D Hartmann; R Lüllmann-Rauch; J Wolff; M Evers; A Köster; M Hetman; K von Figura; C Peters
Journal:  J Biol Chem       Date:  1997-07-25       Impact factor: 5.157

3.  Host cell-specific folding and assembly of the neuronal nicotinic acetylcholine receptor alpha7 subunit.

Authors:  S T Cooper; N S Millar
Journal:  J Neurochem       Date:  1997-05       Impact factor: 5.372

4.  A novel model for the first nucleotide binding domain of the cystic fibrosis transmembrane conductance regulator.

Authors:  J P Annereau; U Wulbrand; A Vankeerberghen; H Cuppens; F Bontems; B Tümmler; J J Cassiman; V Stoven
Journal:  FEBS Lett       Date:  1997-05-05       Impact factor: 4.124

5.  A demonstration using mouse models that successful gene therapy for cystic fibrosis requires only partial gene correction.

Authors:  J R Dorin; R Farley; S Webb; S N Smith; E Farini; S J Delaney; B J Wainwright; E W Alton; D J Porteous
Journal:  Gene Ther       Date:  1996-09       Impact factor: 5.250

6.  CFTR-dependent membrane insertion is linked to stimulation of the CFTR chloride conductance.

Authors:  A Takahashi; S C Watkins; M Howard; R A Frizzell
Journal:  Am J Physiol       Date:  1996-12

7.  Effect of anion transport inhibition on mucus secretion by airway submucosal glands.

Authors:  S K Inglis; M R Corboz; A E Taylor; S T Ballard
Journal:  Am J Physiol       Date:  1997-02

8.  In vivo activation of the cystic fibrosis transmembrane conductance regulator mutant deltaF508 in murine nasal epithelium.

Authors:  T J Kelley; K Thomas; L J Milgram; M L Drumm
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

9.  Defective ATP-dependent mucin secretion by cystic fibrosis pancreatic epithelial cells.

Authors:  C Montserrat; M Merten; C Figarella
Journal:  FEBS Lett       Date:  1996-09-16       Impact factor: 4.124

10.  A delta F508 mutation in mouse cystic fibrosis transmembrane conductance regulator results in a temperature-sensitive processing defect in vivo.

Authors:  P J French; J H van Doorninck; R H Peters; E Verbeek; N A Ameen; C R Marino; H R de Jonge; J Bijman; B J Scholte
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

View more
  74 in total

1.  Choosing sides in the battle against gastric acid.

Authors:  M H Montrose
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

Review 2.  The role of chaperone-assisted folding and quality control in inborn errors of metabolism: protein folding disorders.

Authors:  N Gregersen; P Bross; B S Andrese; C B Pedersen; T J Corydon; L Bolund
Journal:  J Inherit Metab Dis       Date:  2001-04       Impact factor: 4.982

3.  What happens to deltaF508 in vivo?

Authors:  M Drumm
Journal:  J Clin Invest       Date:  1999-05-15       Impact factor: 14.808

Review 4.  Rescuing protein conformation: prospects for pharmacological therapy in cystic fibrosis.

Authors:  Marina S Gelman; Ron R Kopito
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

Review 5.  The unfolded protein response in protein aggregating diseases.

Authors:  Alexander Gow; Ramaswamy Sharma
Journal:  Neuromolecular Med       Date:  2003       Impact factor: 3.843

6.  Intestinal mucins from cystic fibrosis mice show increased fucosylation due to an induced Fucalpha1-2 glycosyltransferase.

Authors:  Kristina A Thomsson; Marina Hinojosa-Kurtzberg; Karin A Axelsson; Steven E Domino; John B Lowe; Sandra J Gendler; Gunnar C Hansson
Journal:  Biochem J       Date:  2002-11-01       Impact factor: 3.857

7.  Processing and function of CFTR-DeltaF508 are species-dependent.

Authors:  Lynda S Ostedgaard; Christopher S Rogers; Qian Dong; Christoph O Randak; Daniel W Vermeer; Tatiana Rokhlina; Philip H Karp; Michael J Welsh
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-14       Impact factor: 11.205

8.  Clinical and molecular characterization of S1118F-CFTR.

Authors:  Himabindu Penmatsa; Carla A Frederick; Sunitha Nekkalapu; Veronica G Conoley; Weiqiang Zhang; Chunying Li; John Kappes; Dennis C Stokes; Anjaparavanda P Naren
Journal:  Pediatr Pulmonol       Date:  2009-10

9.  Tissue-Dependent Expression of Bitter Receptor TAS2R38 mRNA.

Authors:  Jennifer E Douglas; Cailu Lin; Corrine J Mansfield; Charles J Arayata; Beverly J Cowart; Andrew I Spielman; Nithin D Adappa; James N Palmer; Noam A Cohen; Danielle R Reed
Journal:  Chem Senses       Date:  2019-01-01       Impact factor: 3.160

10.  A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy.

Authors:  Kerstin Pohl; Elaine Hayes; Joanne Keenan; Michael Henry; Paula Meleady; Kevin Molloy; Bakr Jundi; David A Bergin; Cormac McCarthy; Oliver J McElvaney; Michelle M White; Martin Clynes; Emer P Reeves; Noel G McElvaney
Journal:  Blood       Date:  2014-06-16       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.